Deka Biosciences, Inc

Check out the latest episode of The BioHub Podcast, featuring Deka's CEO, Dr. John Mumm!

We are incredibly grateful to the team at Plains for their continued support and belief in our mission!

In a recent?Genetic Engineering & Biotechnology News?article, Deka Biosciences CEO Dr. John Mumm highlighted the power of pairing cytokines to drive more effective immunotherapy: “If you really want to push biology in a therapeutically relevant direction with cytokines, you need more than one.” At Deka, we’re pioneering?Diakines?, paired cytokine therapies designed to fine-tune immune responses, maximizing therapeutic benefits while minimizing toxicity. This approach has the potential to reshape treatment strategies for cancer and inflammatory diseases. Learn more in the full article:?https://lnkd.in/eG2HyVGk #Immunotherapy #CancerResearch #Cytokines #Biotech #DekaBiosciences

That's a wrap on JPM 2025! What a wonderful opportunity to share our vision, connect with others in the industry, and explore new pathways to bring cytokine therapeutics closer to the patients who need them. #jpm2025 #innovationinhealthcare

Excited to be at JPM and looking forward to the rest of the week here in San Francisco! #jpm2025

JPM is just one week away! Excited to kick off 2025 by connecting with industry leaders and partners to drive innovation and?explore partnering opportunities in I&I and oncology leveraging the Diakine? platform. If you'll be in San Francisco, send us a message — we'd love to meet. #jpm2025

The Deka team had a fantastic time at SITC last week, sharing our latest research with two poster presentations. Thank you to everyone who stopped by to connect with us. To view the posters, visit our website:?https://lnkd.in/dKxdkb5y #SITC24

We are thrilled to be in Houston this week for #SITC24! A reminder that we will be presenting two posters on Friday, showcasing our latest research. If you're attending the conference, please stop by to learn more about our advancements and connect with our team.

Dr. Abdul Rafeh Naqash from Stephenson Cancer Center at Oklahoma University will be presenting one of our #SITC2024 posters, titled “Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK21?(EGFR) compared to ex vivo Diakine? Response Assay,” sharing key insights from our Phase 1 clinical trial. Thank you, Dr. Naqash, and the brilliant team behind this research: Adanma Ayanambakkam, Alexander Spira, Syed Kazmi, Douglas Orr, Xinhua Zhu, Siqing Fu, Abhishek Tripathi, Aurelien Marabelle, David Langan, Alice Hsu, Jacob McCright, Steven Dudics, Fatima Hamdan, Benjamin George, Phillip Kuri, Allison Long, Deb Kientop, Stanley Frankel, and John Mumm. #CancerResearch #Biotech #Immunotherapy #DekaBiosciences

We're proud to share our latest research at #SITC2024 with two different posters. One of them, titled "Balanced Diakine? targeted cytokines localize within the immunological synapse and augment immune response in combination with T cell engagers," will be presented by Dr. Jacob McCright from Deka. A huge thank you to Jacob and the incredible team behind this work: Steven Dudics, Alice Hsu, David Langan, Benjamin George, Phillip Kuri, Antony Haider, Karen Huang, Fatima Hamdan, Javier Goitia, Julie Ahn, Christopher Yaen, Stanley Frankel, and John Mumm. Together, we’re advancing the field of immunotherapy by exploring new ways to strengthen immune responses and develop more effective treatments for patients. #Biotech #Cytokines #CancerResearch #DekaBiosciences